The cluster shows active-manager conviction (Janus, Avoro, Farallon) outweighing quant selling, but the 45-day lag means current positioning may differ. Watch for next earnings/catalyst update (pipeline data readouts) and any further insider buying to confirm the bullish thesis. The mixed signal suggests a wait-and-see approach rather than immediate directional bet.
Executive Summary
During Q3 2024, DYN saw a mixed institutional cluster: 10 buyers (accumulating $136.9M) faced off against 7 sellers (reducing $100.5M), with active managers like Janus Henderson, Avoro Capital, and Farallon adding large positions while quant funds Citadel and Point72 trimmed significantly. The net $36.4M inflow suggests cautious optimism, but the 45-day 13F reporting lag and divergent quant selling temper conviction.
Key Financial Metrics
Institutional Positions
Net institutional flow: $36.4M
▲ Buyers (10)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Janus Henderson Group | ADD | +47.3% | $244.8M | $81.5M |
| Avoro Capital Advisors | DOUBLED | +461.6% | $23.3M | $19.3M |
| Farallon Capital Management | DOUBLED | +7033.3% | $15.4M | $15.2M |
| Norges Bank | DOUBLED | +303.7% | $15.5M | $11.8M |
| Ameriprise Financial | DOUBLED | +718% | $7.6M | $6.7M |
▼ Sellers (7)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citadel | TRIM | -31.9% | $152.3M | -$46.7M |
| Adage Capital Partners GP | TRIM | -27.8% | $117.4M | -$31.1M |
| Point72 | TRIM | -71.3% | $12.6M | -$8.9M |
| Invesco | NEAR_EXIT | -83.7% | $9.2M | -$7.6M |
Key Facts
- 10 institutional buyers added $136.9M in new positions; 7 sellers reduced by $100.5M (net +$36.4M)
- Janus Henderson Group added $81.5M (current $244.8M); Avoro Capital added $19.3M; Farallon added $15.2M
- Citadel trimmed $46.7M (current $105.6M); Adage Capital trimmed $31.1M; Point72 trimmed $8.9M
- Invesco near-exited (-83.7% of shares), indicating passive rebalancing or risk reduction
- 85% analyst bullish consensus; 4 insider buys totaling $157K in the last 30 days
- 13F data is as of Q3 2024 end; positions may have changed since the filing date
Financial Impact
Net institutional accumulation of $36.4M: $136.9M in buying vs $100.5M in selling during Q3 2024
Risk Factors
- 45-day 13F disclosure lag; positions may have been unwound or adjusted since quarter-end
- Significant quant selling (Citadel, Point72) suggests professional short-term bearish thesis or risk management
- Dyne Therapeutics is a pre-revenue biotech with binary pipeline risk; clinical trial results could reverse the accumulation thesis
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-DYN-2024-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | — |
Aug 14, 2026 7w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | — |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | — |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | — |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | — |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | — |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | — |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | — |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | — |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access